go grey glp 1 A Closer Look at the Dermatological Profile of GLP-1 Agonists GLP-1s 101: What the science
Description
compared with placebo, treatment with GLP-1RA was associated with a 16% and 6% lower risk of MACE in patients with or without preexisting CV disease, respectively (Table 2)
GLP-1RAs work by increasing the levels of the hormone glucagon-like peptide-1 (GLP-1) in the body
Consistency with the medication and lifestyle changes is the key to seeing results
The STEP trial series, which enrolled over 4,000 participants, showed depression rates similar to placebo groups
A practical, three-step approach adapted from current World Health Organization (56), American College of Sports Medicine (57), American Diabetes Association (58), and European Association for the Study of Obesity (59) guidelines is recommended: (1) introduce regular movement gradually, targeting 150 minutes of moderate-intensity or 75 minutes of vigorous aerobic activity per week (60)
A meta-analysis of 10 trials totaling 71,351 patients extended these findings, showing GLP-1 receptor agonists reduced the composite kidney outcome by 17% across trials
